This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, H. Articles by DeClue, J. E. Search for Related Content PubMed PubMed Citation Articles by Li, H. Articles by DeClue, J. E.

Epidermal Growth Factor Receptor Signaling Pathways Are Associated with Tumorigenesis in the Nf1:p53 Mouse Tumor Model

Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892 [H. L., W. C. V., J. E. D.], and Center for Developmental Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75235-9133 [S. V-M., L F. P.]

The human disease neurofibromatosis type 1 (NF1) is caused by mutations in the NF1 gene, and is characterized by the formation of benign and malignant tumors of the peripheral nervous system. We have shown previously that aberrant expression of the epidermal growth factor receptor (EGFR) is a common feature of human NF1-related tumor development in humans and in NF1 animal models. One recent approach taken to investigate the changes associated with NF1 tumor formation is the development of the Nf1:p53 mouse tumor model. Here, we examined a series of tumor cell lines derived from Nf1:p53 mice for their expression of EGFR family members. Immunoblotting analyses revealed that 23 of the 24 cell lines examined express the EGFR, and 24 of 24 express the related tyrosine kinase erbB2, whereas erbB3 was detected in only 6 of 24. All of the cell lines expressing EGFR responded to epidermal growth factor (EGF) by activation of the downstream signaling pathways, mitogen-activated protein (MAP)/extracellular signal-regulated kinase kinase/MAP kinase, and phosphatidylinositol 3'-kinase (PI3k)/AKT. Growth of the cell lines was greatly stimulated by EGF in vitro and could be blocked by an antagonist of the EGFR. In addition, inhibition of the PI3k pathway potently inhibited the EGF-dependent growth of these cell lines, whereas inhibition of the MAP/extracellular signal-regulated kinase kinase/MAP kinase pathway had more limited effects. We conclude that EGFR expression is a common feature of the Nf1:p53 tumor cell lines and that inhibition of this molecule or its downstream target PI3k, may be useful in the treatment of NF1-related malignancies.

This article has been cited by other articles:

				C. Y. Zou, K. D. Smith, Q.-S. Zhu, J. Liu, I. E. McCutcheon, J. M. Slopis, F. Meric-Bernstam, Z. Peng, W. G. Bornmann, G. B. Mills, et al. Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor Mol. Cancer Ther., May 1, 2009; 8(5): 1157 - 1168. [Abstract] [Full Text] [PDF]

				H. Tawbi, D. Thomas, D. R. Lucas, J. S. Biermann, S. M. Schuetze, A. L. Hart, R. Chugh, and L. H. Baker Epidermal Growth Factor Receptor Expression and Mutational Analysis in Synovial Sarcomas and Malignant Peripheral Nerve Sheath Tumors Oncologist, April 1, 2008; 13(4): 459 - 466. [Abstract] [Full Text] [PDF]

				N. Holtkamp, E. Malzer, J. Zietsch, A. F. Okuducu, J. Mucha, C. Mawrin, V.-F. Mautner, H.-U. Schildhaus, and A. von Deimling EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy Neuro-oncol, January 1, 2008; 10(6): 946 - 957. [Abstract] [Full Text] [PDF]

				J. Xu, F. A. Ismat, T. Wang, J. Yang, and J. A. Epstein NF1 Regulates a Ras-Dependent Vascular Smooth Muscle Proliferative Injury Response Circulation, November 6, 2007; 116(19): 2148 - 2156. [Abstract] [Full Text] [PDF]

				J. Wu, J. T. Crimmins, K. R. Monk, J. P. Williams, M. E. Fitzgerald, S. Tedesco, and N. Ratner Perinatal Epidermal Growth Factor Receptor Blockade Prevents Peripheral Nerve Disruption in a Mouse Model Reminiscent of Benign World Health Organization Grade I Neurofibroma Am. J. Pathol., May 1, 2006; 168(5): 1686 - 1696. [Abstract] [Full Text] [PDF]

				K. E. Yutzey, M. Colbert, and J. Robbins Ras-Related Signaling Pathways in Valve Development: Ebb and Flow Physiology, December 1, 2005; 20(6): 390 - 397. [Abstract] [Full Text] [PDF]

				M C Velarde, S I Parisek, R R Eason, F A Simmen, and R C M Simmen The secretory leukocyte protease inhibitor gene is a target of epidermal growth factor receptor action in endometrial epithelial cells J. Endocrinol., January 1, 2005; 184(1): 141 - 151. [Abstract] [Full Text] [PDF]

				G. Corfas, M. O. Velardez, C.-P. Ko, N. Ratner, and E. Peles Mechanisms and Roles of Axon-Schwann Cell Interactions J. Neurosci., October 20, 2004; 24(42): 9250 - 9260. [Full Text] [PDF]

				G. A. Mashour, P. H. Driever, M. Hartmann, S. N. Drissel, T. Zhang, B. Scharf, U. Felderhoff-Muser, S. Sakuma, R. E. Friedrich, R. L. Martuza, et al. Circulating Growth Factor Levels Are Associated with Tumorigenesis in Neurofibromatosis Type 1 Clin. Cancer Res., September 1, 2004; 10(17): 5677 - 5683. [Abstract] [Full Text] [PDF]

				S. J. Miller, H. Li, T. A. Rizvi, Y. Huang, G. Johansson, J. Bowersock, A. Sidani, J. Vitullo, K. Vogel, L. M. Parysek, et al. Brain Lipid Binding Protein in Axon-Schwann Cell Interactions and Peripheral Nerve Tumorigenesis Mol. Cell. Biol., March 15, 2003; 23(6): 2213 - 2224. [Abstract] [Full Text] [PDF]